Remember Claris, the 1987 Apple spin-off that made applications like MacWrite, MacPaint and FileMaker? In 1998, Apple brought all of those products in-house again, with the exception of the low ...

Mirum also plans to initiate a phase II study on its recently in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome later in 2025. MIRM's Overdependence on Livmarli for Growth a Woe ...

Two decades ago, Apple was a troubled company in a time of upheaval. Cofounder Steve Jobs, who had officially returned as interim CEO in September 1997, had a plan to return it to health.

Mirum Pharmaceuticals stock has risen nearly 25% since my 'Sell' rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI ...

Mirum Pharmaceuticals, Inc. is headquartered just outside of San Francisco in Foster City, CA. This commercial stage concern is focused in debilitating rare and orphan diseases within its pipeline ...

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%. The company’s lead product is Livmarli (maralixibat ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI ...

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that they have entered into a definitive ...

With Livmarli sales reaching $142 million during its second full year on the market, Mirum Pharmaceuticals’ rare liver disease treatment is off to a solid start in fulfilling its blockbuster ...